{"id":27337,"date":"2025-06-25T14:21:09","date_gmt":"2025-06-25T14:21:09","guid":{"rendered":"https:\/\/www.neuraxpharm.com\/it\/?page_id=27337"},"modified":"2026-06-22T13:46:33","modified_gmt":"2026-06-22T13:46:33","slug":"profilo-di-sicurezza","status":"publish","type":"page","link":"https:\/\/www.neuraxpharm.com\/it\/portafoglio\/sclerosi-multipla\/profilo-di-sicurezza\/","title":{"rendered":"Profilo di sicurezza"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-page\" data-elementor-id=\"27337\" class=\"elementor elementor-27337\" data-elementor-post-type=\"page\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-7d897cb elementor-section-height-min-height elementor-section-items-bottom elementor-section-boxed elementor-section-height-default\" data-id=\"7d897cb\" data-element_type=\"section\" data-e-type=\"section\" data-settings=\"{&quot;jet_parallax_layout_list&quot;:[],&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t\t\t\t<div class=\"elementor-background-overlay\"><\/div>\n\t\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-1827c79\" data-id=\"1827c79\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-inner-section elementor-element elementor-element-c7a3c86 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"c7a3c86\" data-element_type=\"section\" data-e-type=\"section\" data-settings=\"{&quot;jet_parallax_layout_list&quot;:[]}\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-inner-column elementor-element elementor-element-aa7fae0\" data-id=\"aa7fae0\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-8e20a4c elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"8e20a4c\" data-element_type=\"section\" data-e-type=\"section\" data-settings=\"{&quot;jet_parallax_layout_list&quot;:[]}\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-3bbca7a\" data-id=\"3bbca7a\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-inner-section elementor-element elementor-element-7c489b6 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"7c489b6\" data-element_type=\"section\" data-e-type=\"section\" data-settings=\"{&quot;jet_parallax_layout_list&quot;:[]}\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-inner-column elementor-element elementor-element-2ffd242\" data-id=\"2ffd242\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-85602d9 jet-breadcrumbs-align-left elementor-widget elementor-widget-jet-breadcrumbs\" data-id=\"85602d9\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"jet-breadcrumbs.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<div class=\"elementor-jet-breadcrumbs jet-blocks\">\n\t\t<div class=\"jet-breadcrumbs\">\n\t\t<div class=\"jet-breadcrumbs__content\">\n\t\t<div class=\"jet-breadcrumbs__wrap\"><div class=\"jet-breadcrumbs__item\"><a href=\"https:\/\/www.neuraxpharm.com\/it\/\" class=\"jet-breadcrumbs__item-link is-home\" rel=\"home\" title=\"Home\">Home<\/a><\/div>\n\t\t<\/div>\n\t\t<\/div>\n\t\t<\/div><\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-1a32346 elementor-hidden-desktop elementor-hidden-tablet elementor-hidden-mobile elementor-widget elementor-widget-text-editor\" data-id=\"1a32346\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tProfilo di sicurezza di BRIUMVI\u00ae: reazioni avverse<sup>1<\/sup>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-c686f62 elementor-hidden-desktop elementor-hidden-tablet elementor-hidden-mobile elementor-widget elementor-widget-text-editor\" data-id=\"c686f62\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>Le reazioni avverse pi\u00f9 importanti e frequentemente riportate sono le reazioni correlate all&#8217;infusione (45,3%) e le infezioni (55,8%).<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-c2e77cb elementor-hidden-desktop elementor-hidden-tablet elementor-hidden-mobile elementor-widget elementor-widget-heading\" data-id=\"c2e77cb\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<p class=\"elementor-heading-title elementor-size-default\">Riepilogo delle reazioni avverse segnalate in associazione all'uso di ublituximab<sup>1<\/sup><\/p>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-9c8881c elementor-widget elementor-widget-heading\" data-id=\"9c8881c\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<p class=\"elementor-heading-title elementor-size-default\">La maggior parte delle infezioni sono state di gravit\u00e0 da lieve a moderata e consistevano\nprincipalmente in infezioni delle vie respiratorie<sup>1,a<\/sup><\/p>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-c1fab5b elementor-widget elementor-widget-image\" data-id=\"c1fab5b\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img fetchpriority=\"high\" decoding=\"async\" width=\"2560\" height=\"1758\" src=\"https:\/\/static.neuraxpharm.com\/wp-content\/uploads\/sites\/5\/2026\/05\/06065552\/briumvi-safety-profile-img-1-1-1-scaled-1.png\" class=\"attachment-full size-full wp-image-28999\" alt=\"Confronto effetti avversi teriflunomide vs BRIUMVI\" srcset=\"https:\/\/static.neuraxpharm.com\/wp-content\/uploads\/sites\/5\/2026\/05\/06065552\/briumvi-safety-profile-img-1-1-1-scaled-1.png 2560w, https:\/\/static.neuraxpharm.com\/wp-content\/uploads\/sites\/5\/2026\/05\/06065552\/briumvi-safety-profile-img-1-1-1-scaled-1-300x206.png 300w, https:\/\/static.neuraxpharm.com\/wp-content\/uploads\/sites\/5\/2026\/05\/06065552\/briumvi-safety-profile-img-1-1-1-scaled-1-1024x703.png 1024w, https:\/\/static.neuraxpharm.com\/wp-content\/uploads\/sites\/5\/2026\/05\/06065552\/briumvi-safety-profile-img-1-1-1-scaled-1-768x527.png 768w, https:\/\/static.neuraxpharm.com\/wp-content\/uploads\/sites\/5\/2026\/05\/06065552\/briumvi-safety-profile-img-1-1-1-scaled-1-1536x1055.png 1536w, https:\/\/static.neuraxpharm.com\/wp-content\/uploads\/sites\/5\/2026\/05\/06065552\/briumvi-safety-profile-img-1-1-1-scaled-1-2048x1406.png 2048w, https:\/\/static.neuraxpharm.com\/wp-content\/uploads\/sites\/5\/2026\/05\/06065552\/briumvi-safety-profile-img-1-1-1-scaled-1-600x412.png 600w\" sizes=\"(max-width: 2560px) 100vw, 2560px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-2752bbe elementor-hidden-desktop elementor-hidden-tablet elementor-hidden-mobile elementor-widget elementor-widget-text-editor\" data-id=\"2752bbe\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<ul>\n \t<li>Negli studi clinici, i tassi complessivi di infezione di BRIUMVI\u00ae (55,8%) e teriflunomide (54,4%) erano simili.1,2\n<sup>1<\/sup><\/li>\n \t<li><span style=\"background-color: transparent;\">Le infezioni erano prevalentemente di gravit\u00e0 lieve o moderata e consistevano principalmente in infezioni legate al tratto respiratorio.<\/span><sup style=\"background-color: transparent;\">1,b<\/sup><\/li>\n \t<li>Le infezioni gravi sono state il 5,0% e il 2,9% per BRIUMVI\u00ae e teriflunomide, rispettivamente<sup>1<\/sup><\/li>\n \t<li>Si sono verificati 3 decessi correlati a infezioni in pazienti trattati con BRIUMVI\u00ae (encefalite post-morbillo, polmonite e salpingite post-operatoria a seguito di una gravidanza ectopica)<sup>1<\/sup><\/li>\n \t<li>Non sono state riportate infezioni opportunistiche negli studi ULTIMATE I e II.<sup>2<\/sup><\/li>\n \t<li>I tassi di interruzione del trattamento sono stati simili tra i due gruppi, con circa il 90% dei pazienti che ha completato il trattamento di 2 anni in entrambi gli studi ULTIMATE I e II.<sup>2<\/sup><\/li>\n<\/ul>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-8f57814 elementor-widget elementor-widget-text-editor\" data-id=\"8f57814\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<ul>\n \t<li>Le infezioni gravi sono state rispettivamente il 5,0% e il 2,9%\nper BRIUMVI\u00ae e teriflunomide\n<sup>1<\/sup><\/li>\n \t<li><span style=\"background-color: transparent;\">Si sono verificati 3 decessi tra i pazienti in terapia con BRIUMVI\u00ae\n(encefalite post-infettiva da morbillo, polmonite e salpingite\npost-operatoria in seguito a una gravidanza ectopica)<\/span><sup style=\"background-color: transparent;\">1<\/sup><\/li>\n \t<li>Non sono state riferite infezioni opportunistiche negli studi\nULTIMATE I e II<sup>2<\/sup><\/li>\n \t<li>Si \u00e8 verificato un totale di 3 neoplasie, di cui 2 nel gruppo\ncon ublituximab(uterina ed endometriale) e 1 nel gruppo con\nteriflunomide (lingua).<\/li>\n \t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-1ec6988 elementor-hidden-desktop elementor-hidden-tablet elementor-hidden-mobile elementor-widget elementor-widget-text-editor\" data-id=\"1ec6988\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t&nbsp;\n\n<style>\n    .reference-list {<br \/>      display: flex;<br \/>      flex-direction: column;<br \/>      gap: 1em;<br \/>    }<\/p>\n<p>    .reference-item {<br \/>      display: flex;<br \/>      align-items: flex-start;<br \/>    }<\/p>\n<p>    .reference-number {<br \/>      font-size: smaller;<br \/>      margin-right: 5px;<br \/>      vertical-align: super;<br \/>    }<\/p>\n<p>    .reference-text {<br \/>      text-align: left; \/* Alineaci\u00f3n a la izquierda *\/<br \/>    }<br \/>  <\/style>\n\n&nbsp;\n<div class=\"reference-list\">\n<div class=\"reference-item\"><span class=\"reference-text\"><sup>a<\/sup>I sintomi segnalati come IRR entro 24 ore dall&#8217;infusione sono descritti di seguito in \u2018Reazioni correlate all&#8217;infusione\u2019.\n<\/span><\/div>\n<div class=\"reference-item\"><span class=\"reference-text\"><sup>b<\/sup>Le infezioni del tratto respiratorio superiore si sono verificate nel 33,6% dei pazienti trattati con ublituximab e nel 31,8% dei pazienti trattati con teriflunomide.1 Le infezioni del tratto respiratorio inferiore si sono verificate nel 5,1% dei pazienti trattati con ublituximab e nel 4,0% dei pazienti trattati con teriflunomide.<\/span><\/div>\n<\/div>\n&nbsp;\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-7f0fe99 elementor-widget elementor-widget-text-editor\" data-id=\"7f0fe99\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<strong>Gravidanza<\/strong>\n<div class=\"reference-list\">\n<div class=\"reference-item\"><span class=\"reference-text\">Le donne in et\u00e0 fertile devono utilizzare metodi\ncontraccettivi efficaci mentre ricevono ublituximab\ne per almeno 4 mesi dopo l\u2019ultima infusione.<sup>1<\/sup>\n<br>\nSi \u00e8 a conoscenza di un\u2019escrezione di IgG umane nel\nlatte materno nei primi giorni dopo la nascita, scendendo\na concentrazioni basse poco dopo. \u00c8 quindi possibile\nutilizzare BRIUMVI\u00ae in allattamento in caso di esigenze a\nlivello clinico.<sup>1<\/sup>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-e227c05 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"e227c05\" data-element_type=\"section\" data-e-type=\"section\" data-settings=\"{&quot;jet_parallax_layout_list&quot;:[],&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-6be84e3\" data-id=\"6be84e3\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-inner-section elementor-element elementor-element-9da0c74 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"9da0c74\" data-element_type=\"section\" data-e-type=\"section\" data-settings=\"{&quot;jet_parallax_layout_list&quot;:[]}\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-inner-column elementor-element elementor-element-0b2037d\" data-id=\"0b2037d\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-17ddbf6 elementor-widget elementor-widget-heading\" data-id=\"17ddbf6\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">Negli studi ULTIMATE I e II, le reazioni correlate all'infusione (IRR) sono state principalmente di gravit\u00e0 lieve o moderata e sono diminuite ad ogni infusione<sup>2<\/sup><br><br>\n&lt;10% dei pazienti ha manifestato IRR dalla seconda infusione in poi<sup>2<\/sup><\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-1283b85 elementor-widget elementor-widget-image\" data-id=\"1283b85\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img decoding=\"async\" width=\"2560\" height=\"1567\" src=\"https:\/\/static.neuraxpharm.com\/wp-content\/uploads\/sites\/5\/2026\/05\/06065557\/briumvi-safety-profile-img-2-v2-1-scaled-1.png\" class=\"attachment-full size-full wp-image-29000\" alt=\"IRR per dose vaccination schedule percentages\" srcset=\"https:\/\/static.neuraxpharm.com\/wp-content\/uploads\/sites\/5\/2026\/05\/06065557\/briumvi-safety-profile-img-2-v2-1-scaled-1.png 2560w, https:\/\/static.neuraxpharm.com\/wp-content\/uploads\/sites\/5\/2026\/05\/06065557\/briumvi-safety-profile-img-2-v2-1-scaled-1-300x184.png 300w, https:\/\/static.neuraxpharm.com\/wp-content\/uploads\/sites\/5\/2026\/05\/06065557\/briumvi-safety-profile-img-2-v2-1-scaled-1-1024x627.png 1024w, https:\/\/static.neuraxpharm.com\/wp-content\/uploads\/sites\/5\/2026\/05\/06065557\/briumvi-safety-profile-img-2-v2-1-scaled-1-768x470.png 768w, https:\/\/static.neuraxpharm.com\/wp-content\/uploads\/sites\/5\/2026\/05\/06065557\/briumvi-safety-profile-img-2-v2-1-scaled-1-1536x940.png 1536w, https:\/\/static.neuraxpharm.com\/wp-content\/uploads\/sites\/5\/2026\/05\/06065557\/briumvi-safety-profile-img-2-v2-1-scaled-1-2048x1254.png 2048w, https:\/\/static.neuraxpharm.com\/wp-content\/uploads\/sites\/5\/2026\/05\/06065557\/briumvi-safety-profile-img-2-v2-1-scaled-1-600x367.png 600w\" sizes=\"(max-width: 2560px) 100vw, 2560px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-ab4f1da elementor-widget elementor-widget-text-editor\" data-id=\"ab4f1da\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<ul>\n \t<li>Le IRR possono verificarsi e possono includere piressia, brividi, cefalea, tachicardia, nausea, dolore addominale, irritazione della gola, eritema e reazione anafilattica. Possono verificarsi durante l&#8217;infusione o fino a 24 ore dopo l&#8217;infusione1\n<sup>1<\/sup><\/li>\n \t<li>Lo 2,2% dei pazienti ha sperimentato IRR gravi. Non si sono verificate IRR fatali1\n<sup>1<\/sup><\/li>\n \t<li>Un totale di 6 pazienti ha interrotto il trattamento a causa di IRR (5 pazienti con reazioni all&#8217;infusione di grado 2 e 1 paziente con una reazione all&#8217;infusione di grado 4)2\n<sup>2<\/sup><\/li>\n \t<li>Premedicare con un corticosteroide e un antistaminico per via orale o endovenosa per ridurre la frequenza e la gravit\u00e0 delle IRR.1 L&#8217;aggiunta di un antipiretico (ad esempio, paracetamolo) pu\u00f2 essere presa in considerazionea ,1<sup>a ,1<\/sup><\/li>\n<\/ul>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-4b6acd8 elementor-widget elementor-widget-text-editor\" data-id=\"4b6acd8\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<sup>a<\/sup>Negli studi, il paracetamolo orale (650 mg o equivalente) \u00e8 stato utilizzato solo come intervento per i soggetti che hanno manifestato febbre o piressia dopo la dose della prima settimana, o come clinicamente giustificato a discrezione del medico.\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-fd54a97 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"fd54a97\" data-element_type=\"section\" data-e-type=\"section\" data-settings=\"{&quot;jet_parallax_layout_list&quot;:[]}\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-e5a9281\" data-id=\"e5a9281\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-inner-section elementor-element elementor-element-684a82f elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"684a82f\" data-element_type=\"section\" data-e-type=\"section\" data-settings=\"{&quot;jet_parallax_layout_list&quot;:[]}\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-inner-column elementor-element elementor-element-ed47089\" data-id=\"ed47089\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-3dc8685 text-black-links elementor-widget elementor-widget-text-editor\" data-id=\"3dc8685\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t&nbsp;\n\n<style>\n    .reference-list {<br \/>      display: flex;<br \/>      flex-direction: column;<br \/>      gap: 1em;<br \/>    }<\/p>\n<p>    .reference-item {<br \/>      display: flex;<br \/>      align-items: flex-start;<br \/>    }<\/p>\n<p>    .reference-number {<br \/>      font-size: smaller;<br \/>      margin-right: 5px;<br \/>      vertical-align: super;<br \/>    }<\/p>\n<p>    .reference-text {<br \/>      text-align: left;<br \/>    }<\/p>\n<p>    a {<br \/>      color: black;<br \/>      text-decoration: none; \/* Evita el subrayado del enlace *\/<br \/>    }<\/p>\n<p>    a:hover {<br \/>      text-decoration: underline; \/* A\u00f1ade el subrayado al pasar el cursor *\/<br \/>    }<br \/>  <\/style>\n\n&nbsp;\n<div class=\"reference-list\">\n<div class=\"reference-item\"><span class=\"reference-text\">\n<strong>Riferimenti\n<\/strong><br>\n<sup>1<\/sup>Neuraxpharm Pharmaceuticals S.L. BRIUMVI\u00ae, INN-ublituximab. Summary of product characteristics. European Medicines Agency.Disponibile su: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/BRIUMVI-epar-product-information_en.pdf (consultato il 17 novembre 2023)<\/span><\/div>\n\n<div class=\"reference-item\"><span class=\"reference-text\"><sup>2<\/sup>Steinman L, Fox E, Hartung H-P, et al. Ublituximab Versus Teriflunomide in Relapsing Multiple Sclerosis. N Engl J Med. 2022;387(8):704-714.doi:10.1056\/NEJMoa2201904\n<\/span><\/div>\n\n<\/div>\n&nbsp;\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-313bce2 elementor-widget elementor-widget-text-editor\" data-id=\"313bce2\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>Codice materiale: MAT-IT-BRI-0004-1<br \/>Depositato AIFA: 16\/03\/2026<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-9ef681a elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"9ef681a\" data-element_type=\"section\" data-e-type=\"section\" data-settings=\"{&quot;jet_parallax_layout_list&quot;:[],&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-2d1c824\" data-id=\"2d1c824\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-inner-section elementor-element elementor-element-1db9ef1 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"1db9ef1\" data-element_type=\"section\" data-e-type=\"section\" data-settings=\"{&quot;jet_parallax_layout_list&quot;:[]}\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-inner-column elementor-element elementor-element-068cddc\" data-id=\"068cddc\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>Home Profilo di sicurezza di BRIUMVI\u00ae: reazioni avverse1 Le reazioni avverse pi\u00f9 importanti e frequentemente riportate sono le reazioni correlate all&#8217;infusione (45,3%) e le infezioni (55,8%). Riepilogo delle reazioni avverse segnalate in associazione all&#8217;uso di ublituximab1 La maggior parte delle infezioni sono state di gravit\u00e0 da lieve a moderata e consistevano principalmente in infezioni delle [&hellip;]<\/p>\n","protected":false},"author":2493,"featured_media":0,"parent":27270,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"elementor_header_footer","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-27337","page","type-page","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.2 (Yoast SEO v27.8) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Sclerosi Multipla: Profilo Sicurezza BRIUMVI - Neuraxpharm Italia<\/title>\n<meta name=\"description\" content=\"Scopri il profilo di sicurezza di BRIUMVI\u00ae per la sclerosi multipla: infezioni, neoplasie e gravidanza. Approfondisci i dati.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.neuraxpharm.com\/it\/portafoglio\/sclerosi-multipla\/profilo-di-sicurezza\" \/>\n<meta property=\"og:locale\" content=\"it_IT\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Profilo di sicurezza\" \/>\n<meta property=\"og:description\" content=\"Scopri il profilo di sicurezza di BRIUMVI\u00ae per la sclerosi multipla: infezioni, neoplasie e gravidanza. Approfondisci i dati.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.neuraxpharm.com\/it\/portafoglio\/sclerosi-multipla\/profilo-di-sicurezza\/\" \/>\n<meta property=\"og:site_name\" content=\"Neuraxpharm Italia\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-22T13:46:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.neuraxpharm.com\/it\/wp-content\/uploads\/sites\/5\/2026\/05\/briumvi-safety-profile-img-1-1-1-scaled-1.png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Tempo di lettura stimato\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minuti\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.neuraxpharm.com\\\/it\\\/portafoglio\\\/sclerosi-multipla\\\/profilo-di-sicurezza\\\/\",\"url\":\"https:\\\/\\\/www.neuraxpharm.com\\\/it\\\/portafoglio\\\/sclerosi-multipla\\\/profilo-di-sicurezza\\\/\",\"name\":\"Sclerosi Multipla: Profilo Sicurezza BRIUMVI - Neuraxpharm Italia\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.neuraxpharm.com\\\/it\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.neuraxpharm.com\\\/it\\\/portafoglio\\\/sclerosi-multipla\\\/profilo-di-sicurezza\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.neuraxpharm.com\\\/it\\\/portafoglio\\\/sclerosi-multipla\\\/profilo-di-sicurezza\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.neuraxpharm.com\\\/it\\\/wp-content\\\/uploads\\\/sites\\\/5\\\/2026\\\/05\\\/briumvi-safety-profile-img-1-1-1-scaled-1.png\",\"datePublished\":\"2025-06-25T14:21:09+00:00\",\"dateModified\":\"2026-06-22T13:46:33+00:00\",\"description\":\"Scopri il profilo di sicurezza di BRIUMVI\u00ae per la sclerosi multipla: infezioni, neoplasie e gravidanza. Approfondisci i dati.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.neuraxpharm.com\\\/it\\\/portafoglio\\\/sclerosi-multipla\\\/profilo-di-sicurezza\\\/#breadcrumb\"},\"inLanguage\":\"it-IT\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.neuraxpharm.com\\\/it\\\/portafoglio\\\/sclerosi-multipla\\\/profilo-di-sicurezza\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"it-IT\",\"@id\":\"https:\\\/\\\/www.neuraxpharm.com\\\/it\\\/portafoglio\\\/sclerosi-multipla\\\/profilo-di-sicurezza\\\/#primaryimage\",\"url\":\"https:\\\/\\\/static.neuraxpharm.com\\\/wp-content\\\/uploads\\\/sites\\\/5\\\/2026\\\/05\\\/06065552\\\/briumvi-safety-profile-img-1-1-1-scaled-1.png\",\"contentUrl\":\"https:\\\/\\\/static.neuraxpharm.com\\\/wp-content\\\/uploads\\\/sites\\\/5\\\/2026\\\/05\\\/06065552\\\/briumvi-safety-profile-img-1-1-1-scaled-1.png\",\"width\":2560,\"height\":1758,\"caption\":\"Confronto effetti avversi teriflunomide vs BRIUMVI\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.neuraxpharm.com\\\/it\\\/portafoglio\\\/sclerosi-multipla\\\/profilo-di-sicurezza\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portafoglio\",\"item\":\"https:\\\/\\\/www.neuraxpharm.com\\\/it\\\/portafoglio\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sclerosi multipla Briumvi\",\"item\":\"https:\\\/\\\/www.neuraxpharm.com\\\/it\\\/portafoglio\\\/sclerosi-multipla\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Profilo di sicurezza\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.neuraxpharm.com\\\/it\\\/#website\",\"url\":\"https:\\\/\\\/www.neuraxpharm.com\\\/it\\\/\",\"name\":\"Neuraxpharm Italia\",\"description\":\"A European Leader for the CNS products\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.neuraxpharm.com\\\/it\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"it-IT\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sclerosi Multipla: Profilo Sicurezza BRIUMVI - Neuraxpharm Italia","description":"Scopri il profilo di sicurezza di BRIUMVI\u00ae per la sclerosi multipla: infezioni, neoplasie e gravidanza. Approfondisci i dati.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.neuraxpharm.com\/it\/portafoglio\/sclerosi-multipla\/profilo-di-sicurezza","og_locale":"it_IT","og_type":"article","og_title":"Profilo di sicurezza","og_description":"Scopri il profilo di sicurezza di BRIUMVI\u00ae per la sclerosi multipla: infezioni, neoplasie e gravidanza. Approfondisci i dati.","og_url":"https:\/\/www.neuraxpharm.com\/it\/portafoglio\/sclerosi-multipla\/profilo-di-sicurezza\/","og_site_name":"Neuraxpharm Italia","article_modified_time":"2026-06-22T13:46:33+00:00","og_image":[{"url":"https:\/\/www.neuraxpharm.com\/it\/wp-content\/uploads\/sites\/5\/2026\/05\/briumvi-safety-profile-img-1-1-1-scaled-1.png","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Tempo di lettura stimato":"4 minuti"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.neuraxpharm.com\/it\/portafoglio\/sclerosi-multipla\/profilo-di-sicurezza\/","url":"https:\/\/www.neuraxpharm.com\/it\/portafoglio\/sclerosi-multipla\/profilo-di-sicurezza\/","name":"Sclerosi Multipla: Profilo Sicurezza BRIUMVI - Neuraxpharm Italia","isPartOf":{"@id":"https:\/\/www.neuraxpharm.com\/it\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.neuraxpharm.com\/it\/portafoglio\/sclerosi-multipla\/profilo-di-sicurezza\/#primaryimage"},"image":{"@id":"https:\/\/www.neuraxpharm.com\/it\/portafoglio\/sclerosi-multipla\/profilo-di-sicurezza\/#primaryimage"},"thumbnailUrl":"https:\/\/www.neuraxpharm.com\/it\/wp-content\/uploads\/sites\/5\/2026\/05\/briumvi-safety-profile-img-1-1-1-scaled-1.png","datePublished":"2025-06-25T14:21:09+00:00","dateModified":"2026-06-22T13:46:33+00:00","description":"Scopri il profilo di sicurezza di BRIUMVI\u00ae per la sclerosi multipla: infezioni, neoplasie e gravidanza. Approfondisci i dati.","breadcrumb":{"@id":"https:\/\/www.neuraxpharm.com\/it\/portafoglio\/sclerosi-multipla\/profilo-di-sicurezza\/#breadcrumb"},"inLanguage":"it-IT","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.neuraxpharm.com\/it\/portafoglio\/sclerosi-multipla\/profilo-di-sicurezza\/"]}]},{"@type":"ImageObject","inLanguage":"it-IT","@id":"https:\/\/www.neuraxpharm.com\/it\/portafoglio\/sclerosi-multipla\/profilo-di-sicurezza\/#primaryimage","url":"https:\/\/static.neuraxpharm.com\/wp-content\/uploads\/sites\/5\/2026\/05\/06065552\/briumvi-safety-profile-img-1-1-1-scaled-1.png","contentUrl":"https:\/\/static.neuraxpharm.com\/wp-content\/uploads\/sites\/5\/2026\/05\/06065552\/briumvi-safety-profile-img-1-1-1-scaled-1.png","width":2560,"height":1758,"caption":"Confronto effetti avversi teriflunomide vs BRIUMVI"},{"@type":"BreadcrumbList","@id":"https:\/\/www.neuraxpharm.com\/it\/portafoglio\/sclerosi-multipla\/profilo-di-sicurezza\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portafoglio","item":"https:\/\/www.neuraxpharm.com\/it\/portafoglio\/"},{"@type":"ListItem","position":2,"name":"Sclerosi multipla Briumvi","item":"https:\/\/www.neuraxpharm.com\/it\/portafoglio\/sclerosi-multipla\/"},{"@type":"ListItem","position":3,"name":"Profilo di sicurezza"}]},{"@type":"WebSite","@id":"https:\/\/www.neuraxpharm.com\/it\/#website","url":"https:\/\/www.neuraxpharm.com\/it\/","name":"Neuraxpharm Italia","description":"A European Leader for the CNS products","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.neuraxpharm.com\/it\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"it-IT"}]}},"acf":[],"_links":{"self":[{"href":"https:\/\/www.neuraxpharm.com\/it\/wp-json\/wp\/v2\/pages\/27337","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.neuraxpharm.com\/it\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.neuraxpharm.com\/it\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.neuraxpharm.com\/it\/wp-json\/wp\/v2\/users\/2493"}],"replies":[{"embeddable":true,"href":"https:\/\/www.neuraxpharm.com\/it\/wp-json\/wp\/v2\/comments?post=27337"}],"version-history":[{"count":19,"href":"https:\/\/www.neuraxpharm.com\/it\/wp-json\/wp\/v2\/pages\/27337\/revisions"}],"predecessor-version":[{"id":29205,"href":"https:\/\/www.neuraxpharm.com\/it\/wp-json\/wp\/v2\/pages\/27337\/revisions\/29205"}],"up":[{"embeddable":true,"href":"https:\/\/www.neuraxpharm.com\/it\/wp-json\/wp\/v2\/pages\/27270"}],"wp:attachment":[{"href":"https:\/\/www.neuraxpharm.com\/it\/wp-json\/wp\/v2\/media?parent=27337"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}